Loading
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Previous close
$1.72
−$0.02 · -1.15%
Regular session · ET · Market data may be delayed.
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Day range
Current $1.72
52-week range
Current $1.72
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
56
Mixed
Risk
66
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Day range
Current $1.72
52-week range
Current $1.72
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 3.73M USD | 7.62M USD | 17.03M USD | 16.32M USD | 11.83M USD |
| Selling, general, and administrative | 2.98M USD | 2.94M USD | 4.84M USD | 5.96M USD | 5.82M USD |
| Operating expenses | 27.46M USD | 11.01M USD | 22.27M USD | 22.6M USD | 17.93M USD |
| Interest income | 227K USD | 260K USD | 474K USD | 532K USD | 320K USD |
| Interest expense | 39K USD | 41K USD | 56K USD | 67K USD | 79K USD |
| Depreciation and amortization | 203K USD | 186K USD | 197K USD | 201K USD | 231K USD |
| Operating income | −27.46M USD | −11.01M USD | −22.27M USD | −22.6M USD | −17.93M USD |
| Net income | −26.39M USD | −7.24M USD | −19.88M USD | −21.67M USD | −18.38M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
